Cargando…

Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice

Given the role of macrophage-derived high mobility group box 1 (HMGB1) in chemotherapy-induced peripheral neuropathy (CIPN) caused by paclitaxel, we analyzed the role of HMGB1 and macrophages in the CIPN caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent used for the treatment of m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsubota, Maho, Miyazaki, Takaya, Ikeda, Yuya, Hayashi, Yusuke, Aokiba, Yui, Tomita, Shiori, Sekiguchi, Fumiko, Wang, Dengli, Nishibori, Masahiro, Kawabata, Atsufumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533714/ https://www.ncbi.nlm.nih.gov/pubmed/34685531 http://dx.doi.org/10.3390/cells10102550

Ejemplares similares

Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants
por: Tsubota, Maho, et al.
Publicado: (2019)

Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy
por: Sekiguchi, Fumiko, et al.
Publicado: (2020)

Macrophage as a Peripheral Pain Regulator
por: Domoto, Risa, et al.
Publicado: (2021)

Cystitis-Related Bladder Pain Involves ATP-Dependent HMGB1 Release from Macrophages and Its Downstream H(2)S/Ca(v)3.2 Signaling in Mice
por: Hiramoto, Shiori, et al.
Publicado: (2020)

HMGB1 Translocation in Neurons after Ischemic Insult: Subcellular Localization in Mitochondria and Peroxisomes
por: Wang, Dengli, et al.
Publicado: (2020)

Anti-high mobility group box-1 (HMGB1) antibody inhibits hemorrhage-induced brain injury and improved neurological deficits in rats
por: Wang, Dengli, et al.
Publicado: (2017)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

A hydrolysate of poly-trans-[(2-carboxyethyl)germasesquioxane] (Ge-132) suppresses Ca(v)3.2-dependent pain by sequestering exogenous and endogenous sulfide
por: Sekiguchi, Fumiko, et al.
Publicado: (2022)

The chemotherapeutic agent bortezomib induces the formation of stress granules
por: Fournier, Marie-Josée, et al.
Publicado: (2010)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy
por: Lohberger, Birgit, et al.
Publicado: (2016)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Corticosterone Induces HMGB1 Release in Primary Cultured Rat Cortical Astrocytes: Involvement of Pannexin-1 and P2X7 Receptor-Dependent Mechanisms
por: Hisaoka-Nakashima, Kazue, et al.
Publicado: (2020)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Anti-high mobility group box-1 (HMGB1) antibody attenuates delayed cerebral vasospasm and brain injury after subarachnoid hemorrhage in rats
por: Haruma, Jun, et al.
Publicado: (2016)

Proteasome inhibition by bortezomib: A left hook and a right punch
por: Roelofs, Jeroen
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
por: Roy, Mridul, et al.
Publicado: (2016)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
por: Zhou, Liang
Publicado: (2022)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan
por: Hiramoto, Shiori, et al.
Publicado: (2021)

The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib
por: Milano, A, et al.
Publicado: (2009)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
por: Moreira, Wilfried, et al.
Publicado: (2017)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

High Mobility Group Box-1 and Blood–Brain Barrier Disruption
por: Nishibori, Masahiro, et al.
Publicado: (2020)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
por: Sridhar, Settu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0dk7ajq8fp7f9imveid2e1p2rf